Find, compare & contact
Desmethylsertraline
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Desmethylsertraline API 87857-41-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Desmethylsertraline. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Desmethylsertraline
- Synonyms:
- Demethylsertraline , N-Demethylsertraline , N-Norsertraline
- Cas Number:
- 87857-41-8
- DrugBank number:
- DB14071
- Unique Ingredient Identifier:
- CJJ71O9BE8
General Description:
Desmethylsertraline, identified by CAS number 87857-41-8, is a notable compound with significant therapeutic applications. Desmethylsertraline is a metabolite of sertraline.
Categories:
Desmethylsertraline is categorized under the following therapeutic classes: Agents that reduce seizure threshold, Amines, Naphthalenes, P-glycoprotein inhibitors. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Desmethylsertraline is a type of Antimetabolites
Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.
One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.
Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.
Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.
In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.
